Bioventus came in with another set of strong numbers in Q2. We reiterate the buy thesis on BVS and note there are numerous idiosyncratic risk premia on offer. The company has sorted its transaction of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback